Medtronic Launches Back Pain Trial

Medical device maker Medtronic (NYSE: MDT  ) announced in a press statement Monday that it has begun a clinical trial  testing neurostimulation therapy of its Specify 5-6-5 spinal cord stimulation treatment. The first-of-its-kind trial will evaluate the company's therapy for patients suffering from failed back surgery syndrome (FBSS) and predominant low back pain.

The company's study, dubbed PROMISE, will evaluate up to  300 patients from across the globe. Medtronic estimates around 10% of the entire U.S. population lives with back pain; the company further projects that 20% of European adults also suffer from chronic pain. The company's neurostimulation therapy has treated more than 250,000 people so far, according to Medtronic.

PROMISE's principal investigator, Dr. Phillipe Rigoard, said in the release:

Spinal cord stimulation has become an increasingly valued treatment approach in chronic pain, and we look forward to participating in the latest study... If the PROMISE results are positive, they will provide critically needed relief for those patients suffering from chronic low back pain associated with FBSS.

Medtronic is looking for a 50% reduction  in reported pain from study patients following the beginning of therapy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2226042, ~/Articles/ArticleHandler.aspx, 4/20/2014 12:32:15 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement